Return to homepagePandemic Pact

Antiviral compounds against CoV-2 helicase (Antiviralt läkemedel mot CoV-2 helicase)

Grant number: 2020-05836

Grant search

Key facts

  • Disease

    COVID-19

  • start year

    2020

  • Known Financial Commitments (USD)

    $69,187.74

  • Funder

    Swedish Research Council

  • Principal Investigator

    Anders Sönnerborg

  • Research Location

    Sweden

  • Lead Research Institution

    Karolinska Institutet

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

We have discovered a compound that inhibits nsp13 of SARS-CoV nsp13, MERS-CoV and mouse hepatitis coronavirus. We hypothesize that the compound and its derivates inhibit CoV-2 helicase, with the same mechanism of action. Thereby broad-spectrum coronavirus inhibitors can be identified. Hence, in the project we will determine the inhibition mechanism of the lead compound on SARS-CoV-2 and identify broad-spectrum related compounds which will be evaluated in vitro assays for cytotoxicity and antiviral efficacy. Also any drug resistance pattern will be determined. Mikrobiologi inom det medicinska området

Publicationslinked via Europe PMC

Last Updated:14 hours ago

View all publications at Europe PMC

Infectivity of SARS-CoV-2: there Is Something More than D614G?